To evaluate the efficacy of ralizumab combined with Traditional Chinese medicine in the treatment of macular edema secondary to retinal vein occlusion based on a real-world study
Phase 1
- Conditions
- retinal vein occlusion
- Registration Number
- ITMCTR2200005968
- Lead Sponsor
- Shenzhen Traditional Chinese Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
18-80 years old RVO secondary macular edema, TCM syndromes conform to spleen deficiency phlegm-dampness type
Exclusion Criteria
1. RVO patients are younger than 18 years old or older than 80 years old;
2. TCM syndromes of RVO patients do not conform to the type of spleen deficiency and phlegm-dampness;
3. RVO patients have severe proliferative retinopathy or retinal detachment;
4. Patients with RVO receive systemic or local (vitreous injection) hormones.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method best corrected visual acuity,BCVA;Number of ralizumab injections within 1 year;Number of ralizumab injections within 1 year;Macular edema;
- Secondary Outcome Measures
Name Time Method Macular pucker;Vitreous hemorrhage;